HIV Integrase Inhibitor Pharmacogenetics and Clinical Outcomes: An Exploratory Association Study

As HIV is now primarily a chronic condition, treatment is given life-long with changes as necessitated by alterations in tolerability and efficacy. Thus, personalized medicine may be useful in the prevention of unnecessary drug exposure and avoidable side effects. Three of the four currently availab...

Full description

Bibliographic Details
Main Author: Murrell, Derek E
Format: Others
Language:English
Published: Digital Commons @ East Tennessee State University 2018
Subjects:
HIV
Online Access:https://dc.etsu.edu/etd/3465
https://dc.etsu.edu/cgi/viewcontent.cgi?article=4926&context=etd
id ndltd-ETSU-oai-dc.etsu.edu-etd-4926
record_format oai_dc
spelling ndltd-ETSU-oai-dc.etsu.edu-etd-49262019-05-16T05:06:19Z HIV Integrase Inhibitor Pharmacogenetics and Clinical Outcomes: An Exploratory Association Study Murrell, Derek E As HIV is now primarily a chronic condition, treatment is given life-long with changes as necessitated by alterations in tolerability and efficacy. Thus, personalized medicine may be useful in the prevention of unnecessary drug exposure and avoidable side effects. Three of the four currently available HIV integrase strand transfer inhibitors (INSTIs), raltegravir, elvitegravir, and dolutegravir, are widely utilized antiretrovirals in the USA and exhibit variations in outcomes among subjects. To interrogate differences among subjects receiving these drugs, we investigated the association of several single nucleotide polymorphisms (SNPs) with drug exposure, clinical outcomes, and subject-reported adverse events. HIV+ adults (≥18 years old) receiving an INSTI regimen were recruited (n=88). Subject genotypes were evaluated using an iPLEX PGx Panel. Genetic variations within our population, underwent multiple regression with covariates [age, sex, BMI, regimen duration, and baseline variables (as required) along with specific regimen in the comprehensive group] to detect significant (p=0.028) between abnormal dream occurrence and specific INSTI regimen with the raltegravir grouping presenting a higher frequency. This exploratory study also discovered several SNP-outcome associations when using INSTIs. Although these SNPs were found to have a role in predicting segments of adverse effect profiles, the clinical significance of these findings remains to be determined. Larger studies will be needed to confirm these exploratory findings with functional studies to understand pathogeneses. In conclusion, the associations found in this study strengthen the need for further assessment, within the HIV+ population, of factors contributing to unfavorable subject outcomes. 2018-08-01T07:00:00Z text application/pdf https://dc.etsu.edu/etd/3465 https://dc.etsu.edu/cgi/viewcontent.cgi?article=4926&context=etd Copyright by the authors. Electronic Theses and Dissertations eng Digital Commons @ East Tennessee State University Dolutegravir Elvitegravir Raltegravir Pharmacogenetics HIV Adverse events Other Pharmacy and Pharmaceutical Sciences Pharmacology Virus Diseases
collection NDLTD
language English
format Others
sources NDLTD
topic Dolutegravir
Elvitegravir
Raltegravir
Pharmacogenetics
HIV
Adverse events
Other Pharmacy and Pharmaceutical Sciences
Pharmacology
Virus Diseases
spellingShingle Dolutegravir
Elvitegravir
Raltegravir
Pharmacogenetics
HIV
Adverse events
Other Pharmacy and Pharmaceutical Sciences
Pharmacology
Virus Diseases
Murrell, Derek E
HIV Integrase Inhibitor Pharmacogenetics and Clinical Outcomes: An Exploratory Association Study
description As HIV is now primarily a chronic condition, treatment is given life-long with changes as necessitated by alterations in tolerability and efficacy. Thus, personalized medicine may be useful in the prevention of unnecessary drug exposure and avoidable side effects. Three of the four currently available HIV integrase strand transfer inhibitors (INSTIs), raltegravir, elvitegravir, and dolutegravir, are widely utilized antiretrovirals in the USA and exhibit variations in outcomes among subjects. To interrogate differences among subjects receiving these drugs, we investigated the association of several single nucleotide polymorphisms (SNPs) with drug exposure, clinical outcomes, and subject-reported adverse events. HIV+ adults (≥18 years old) receiving an INSTI regimen were recruited (n=88). Subject genotypes were evaluated using an iPLEX PGx Panel. Genetic variations within our population, underwent multiple regression with covariates [age, sex, BMI, regimen duration, and baseline variables (as required) along with specific regimen in the comprehensive group] to detect significant (p=0.028) between abnormal dream occurrence and specific INSTI regimen with the raltegravir grouping presenting a higher frequency. This exploratory study also discovered several SNP-outcome associations when using INSTIs. Although these SNPs were found to have a role in predicting segments of adverse effect profiles, the clinical significance of these findings remains to be determined. Larger studies will be needed to confirm these exploratory findings with functional studies to understand pathogeneses. In conclusion, the associations found in this study strengthen the need for further assessment, within the HIV+ population, of factors contributing to unfavorable subject outcomes.
author Murrell, Derek E
author_facet Murrell, Derek E
author_sort Murrell, Derek E
title HIV Integrase Inhibitor Pharmacogenetics and Clinical Outcomes: An Exploratory Association Study
title_short HIV Integrase Inhibitor Pharmacogenetics and Clinical Outcomes: An Exploratory Association Study
title_full HIV Integrase Inhibitor Pharmacogenetics and Clinical Outcomes: An Exploratory Association Study
title_fullStr HIV Integrase Inhibitor Pharmacogenetics and Clinical Outcomes: An Exploratory Association Study
title_full_unstemmed HIV Integrase Inhibitor Pharmacogenetics and Clinical Outcomes: An Exploratory Association Study
title_sort hiv integrase inhibitor pharmacogenetics and clinical outcomes: an exploratory association study
publisher Digital Commons @ East Tennessee State University
publishDate 2018
url https://dc.etsu.edu/etd/3465
https://dc.etsu.edu/cgi/viewcontent.cgi?article=4926&context=etd
work_keys_str_mv AT murrelldereke hivintegraseinhibitorpharmacogeneticsandclinicaloutcomesanexploratoryassociationstudy
_version_ 1719189349581455360